UCB Canada. "We are pleased and proud of the positive recommendations made by both CDA and INESSS on behalf of BIMZELX for the treatment of PsA and AS. Our hope is that with pCPA negotiations ...

3 Health Canada's approvals of RYSTIGGO and ZILBRYSQ for adults with gMG demonstrates UCB's commitment to advancing science in severe neurological and autoimmune diseases, addressing the gMG ...

Recognizing the urgent need to address this diagnostic delay, UCB has launched FASTRAX Canada. This innovative program aims to implement and expand an interdisciplinary model of care integrating ...

3 Health Canada's approvals of RYSTIGGO and ZILBRYSQ for adults with gMG demonstrates UCB's commitment to advancing science in severe neurological and autoimmune diseases, addressing the gMG community ...